NASDAQ:BPTH Bio-Path (BPTH) Stock Price, News & Analysis $1.71 -0.07 (-3.93%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$1.70▼$1.8450-Day Range$1.71▼$3.2352-Week Range$1.70▼$31.40Volume37,500 shsAverage Volume1.24 million shsMarket Capitalization$3.56 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends Get Bio-Path alerts: Email Address Bio-Path MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,239.2% Upside$40.00 Price TargetShort InterestHealthy3.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.53) to ($3.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.43 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBio-Path has only been the subject of 1 research reports in the past 90 days.Read more about Bio-Path's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.97% of the float of Bio-Path has been sold short.Short Interest Ratio / Days to CoverBio-Path has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Path has recently increased by 159.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBio-Path does not currently pay a dividend.Dividend GrowthBio-Path does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPTH. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Path insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.05% of the stock of Bio-Path is held by insiders.Percentage Held by InstitutionsOnly 5.74% of the stock of Bio-Path is held by institutions.Read more about Bio-Path's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bio-Path are expected to grow in the coming year, from ($5.53) to ($3.65) per share.Price to Book Value per Share RatioBio-Path has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bio-Path's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.I have uncovered a bombshell that changes everything… and threatens everything. About Bio-Path Stock (NASDAQ:BPTH)Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Read More BPTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPTH Stock News HeadlinesJune 14, 2024 | investorplace.comWhy Is Bio-Path (BPTH) Stock Up 20% Today?June 14, 2024 | globenewswire.comBio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association CongressJuly 8, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.June 5, 2024 | globenewswire.comBio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesJune 3, 2024 | globenewswire.comBio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual MeetingMay 24, 2024 | globenewswire.comBio-Path Holdings to Present Data at 2024 European Hematology Association CongressMay 23, 2024 | globenewswire.comBio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual MeetingMay 16, 2024 | finance.yahoo.comBio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...July 8, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.May 15, 2024 | finanznachrichten.deBio-Path Holdings, Inc.: Bio-Path Holdings Reports First Quarter 2024 Financial ResultsMay 15, 2024 | msn.comBio-Path GAAP EPS of -$4.88 misses by $0.34May 15, 2024 | globenewswire.comBio-Path Holdings Reports First Quarter 2024 Financial ResultsMay 8, 2024 | globenewswire.comBio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024May 2, 2024 | benzinga.comLooking Into Bio-Path Hldgs's Recent Short InterestApril 19, 2024 | globenewswire.comBio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 18, 2024 | msn.comCrude Oil Edges Lower; Bio-Path Holdings Shares Spike HigherApril 18, 2024 | msn.comWhy Bio-Path Stock Is SoaringApril 18, 2024 | globenewswire.comBio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesSee More Headlines Receive BPTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/07/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BPTH CUSIPN/A CIK1133818 Webwww.biopathholdings.com Phone(832) 742-1357FaxN/AEmployees10Year Founded2007Price Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+2,239.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,037.30% Return on Assets-337.80% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book2.41Miscellaneous Outstanding Shares2,080,000Free Float2,017,000Market Cap$3.56 million OptionableOptionable Beta0.28 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Peter H. Nielsen MBA (Age 75)Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer Comp: $696.24kMr. Douglas P. Morris (Age 68)Co-Founder, Director of Investor Relations, Secretary & Director Comp: $73.74kMr. Michael Hickey M.B.A.VP of Clinical OperationsMr. Anthony PriceSenior Vice President of Finance, Accounting & AdministrationDr. Ana Tari Ashizawa Ph.D.MBA, Senior Vice President of Research, Development & Clinical DesignKey CompetitorsCara TherapeuticsNASDAQ:CARAKintara TherapeuticsNASDAQ:KTRAEdesa BiotechNASDAQ:EDSABullfrog AINASDAQ:BFRGKiora PharmaceuticalsNASDAQ:KPRXView All Competitors BPTH Stock Analysis - Frequently Asked Questions How have BPTH shares performed this year? Bio-Path's stock was trading at $9.26 at the beginning of 2024. Since then, BPTH shares have decreased by 81.5% and is now trading at $1.71. View the best growth stocks for 2024 here. How were Bio-Path's earnings last quarter? Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its earnings results on Wednesday, May, 15th. The company reported ($4.88) earnings per share for the quarter, missing analysts' consensus estimates of ($4.54) by $0.34. When did Bio-Path's stock split? Shares of Bio-Path reverse split on the morning of Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Bio-Path? Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN). This page (NASDAQ:BPTH) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
